[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 28, 2001

Postexposure Rabies Prophylaxis in Immunosuppressed Patients

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(12):1574-1575. doi:10.1001/jama.285.12.1574

To the Editor: In their Research Letter describing treatment for rabies in a patient with lymphoma, Dr Hay and colleagues1 recommended doubling the dose of rabies vaccine and postponing chemotherapy. However, we believe that several issues surrounding rabies postexposure prophylaxis (PEP) require clasification.

First, an assay for antibodies is used to detect an immune response against rabies virus, not to define protection.2 Therefore, "acceptable" response is a more preferred term than "protective" response. The rapid fluorescent focus inhibition test is the current viral neutralization test of choice for human sera.3,4 The Advisory Committee on Immunization Practices (ACIP) has recommended that complete neutralization of virus at a serum dilution of 1:5 is acceptable.3 The World Health Organization recommends a more conservative level of 0.5 IU/mL (a titer of approximately 1:50 by serum dilution).4 Both of these values are arbitrary laboratory standards and neither equates with protection.

First Page Preview View Large
First page PDF preview
First page PDF preview
×